Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Umbreen Rozell
Assistant Clinical Professor, Medicine - (Clinical Series Track)
Medicine
Full Page
Overview
Research
More
Collaboration
(14)
Rachna Shroff
Mutual work: 5 Proposals﹒5 Grants
Collaboration Details
Jennifer Segar
Mutual work: 4 Grants﹒6 Proposals
Collaboration Details
Hina Arif Tiwari
Mutual work: 4 Grants﹒4 Proposals
Collaboration Details
Gregory Woodhead
Mutual work: 1 Grant﹒1 Proposal
Collaboration Details
Sima Ehsani Chimeh
Mutual work: 4 Grants﹒6 Proposals
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(9)
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for
Active
·
2024
·
$0 / $252.6K
·
External
Co-Investigator (COI)
breast cancer,
adjuvant therapy,
immunotherapy,
clinical trial,
hormone receptor
Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have R
Active
·
2023
·
$0 / $709.8K
·
External
Co-Investigator (COI)
breast cancer,
immunotherapy,
clinical trials,
combination therapy,
precision medicine
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Active
·
2023
·
$0 / $568.2K
·
External
Co-Investigator (COI)
colorectal cancer,
treatment,
clinical trial,
dkn-01,
chemotherapy
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Active
·
2023
·
$0 / $494.2K
·
External
Co-Investigator (COI)
cancer,
immunotherapy,
clinical trials,
metastasis,
treatment comparison
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of
Active
·
2023
·
$0 / $342.9K
·
External
Co-Investigator (COI)
cancer treatment,
drug combination,
efficacy,
safety
Page 1 of 2
Previous page
Next page
Publications
(3)
Recent
Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study.
2023
immunotherapy,
cancer,
ethnicity,
clinical trial,
treatment response
New Oral Anticoagulants and Their Reversal
2015
anticoagulants,
pharmacology,
hematology,
drug safety,
clinical trials
Pervasive and largely lineage-specific adaptive protein evolution in the dosage compensation complex of Drosophila melanogaster
2007